Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2025-10-15 00:00:00 ET · period of report 2025-10-10 · accession 0001193125-25-240662 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-15 | 2025-10-10 | NDRA | DIGIANDOMENICO ANTHONY | Dir | A - Grant | $7.06 | +70.8K | 76.3K | +1,301% | +$500.0K |
| D | 2025-10-15 | 2025-10-10 | NDRA | DIGIANDOMENICO ANTHONY | Dir | A - Grant | $7.06 | +141.6K | 141.6K | New | +$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-10 | A | A | 70,822 | $7.06 | 76,265 | D | — | — | (F2) Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock. (F3) Includes unvested restricted stock units. |
| 2 | Derivative | Warrants | 2025-10-10 | A | A | 141,644 | $7.06 | 141,644 | D | $6.81 · 2025-10-15 to 2030-10-15 | 141,644 Common Stock | (F2) Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock. |